Initial [tmco]
treatment [ftcn]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
Rosiglitazone + glimepiride [orch, phsu]
Patients [podg]
untreated [fndg]
Type 2 Diabetes [dsyn]
Study [mnob]
Assessed [acty]
Efficacy [qlco]
Safety [hcpp]
Dose Regimen [topp]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
Rosiglitazone + glimepiride [orch, phsu]
Plus [qlco]
Compared [acty]
rosiglitazone [orch, phsu]
glimepiride [orch, phsu]
Drug [phsu]
Subject [grup]
Diabetes Mellitus, Type 2 [dsyn]
Methods [inpr]
Drug [phsu]
Subject [grup]
N NOS [aapp, imft]
DOUBLE BLIND [resa]
Parallel Study [resa]
Group [idcn]
Glycosylated haemoglobin A [aapp, bacs]
HbA [aapp, bacs]
Subject [grup]
randomized [resa]
Receive [qlco]
glimepiride [orch, phsu]
mg% [qnco]
Once daily [tmco]
OD [dsyn]
Maximal [qlco]
rosiglitazone [orch, phsu]
mg% [qnco]
OD [dsyn]
Maximal [qlco]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose Regimen [topp]
Combination [qlco]
mg/mg [qnco]
OD [dsyn]
Maximal [qlco]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
Regimen B [topp]
mg/mg [qnco]
OD [dsyn]
Maximal [qlco]
Patients [podg]
Assessed [acty]
Efficacy [qlco]
Safety [hcpp]
4 Weeks [tmco]
weeks [tmco]
Study [mnob]
weeks [tmco]
Primary Endpoint [irda]
Efficacy [qlco]
HbA [aapp, bacs]
baseline [bodm]
secondary [neop]
endpoints [qlco]
included [ftcn]
Proportion [qnco]
Patients [podg]
Recommended [idcn]
HbA [aapp, bacs]
Fasting [fndg]
Plasma glucose [lbpr]
Target [ftcn]
baseline [bodm]
Fasting [fndg]
Plasma glucose [lbpr]
Insulin [aapp, horm, phsu]
C-reactive protein [aapp, imft]
Adiponectin [aapp, bacs]
Free Fatty Acids [lipd]
Lipids [lipd]
Percentage [qnco]
Homeostasis model assessment [lbpr]
Estimated [qnco]
Insulin Sensitivity [patf]
Beta cell [cell]
function [phsf]
Safety [hcpp]
Evaluations [ftcn]
included [ftcn]
Adverse event [fndg]
Monitoring [hlca]
Clinical evaluation [hlca]
Laboratory [mnob, orgt]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose Reduced [topp]
Combination [qlco]
regimens [inpr]
HbA [aapp, bacs]
Fixed [fndg]
Dose Regimen [topp]
Combination [qlco]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
Regimen B [topp]
Great extent [qlco]
rosiglitazone [orch, phsu]
glimepiride [orch, phsu]
Adjusted [ftcn]
treatment [ftcn]
P NOS [aapp, imft]
rosiglitazone [orch, phsu]
glimepiride [orch, phsu]
Subject [grup]
HbA [aapp, bacs]
Target [ftcn]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose Regimen [topp]
Combination [qlco]
Compared [acty]
rosiglitazone [orch, phsu]
glimepiride [orch, phsu]
Alone [qnco]
Adjusted [ftcn]
Odds Ratio [qnco]
P NOS [aapp, imft]
Comparison [acty]
reduction [npop]
Fasting [fndg]
plasma glucose level [lbtr]
Observed [ftcn]
Subject [grup]
treated [topp]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
mg dl [qnco]
Fixed [fndg]
Dose Regimen [topp]
Combination [qlco]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
Regimen B [topp]
Compared [acty]
rosiglitazone [orch, phsu]
glimepiride [orch, phsu]
Adjusted [ftcn]
treatment [ftcn]
P NOS [aapp, imft]
Comparison [acty]
Improvement [cnce]
C-reactive protein [aapp, imft]
Observed [ftcn]
Subject [grup]
treated [topp]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
rosiglitazone [orch, phsu]
Compared [acty]
glimepiride [orch, phsu]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
Well [qlco]
Safety [hcpp]
TOLERABILITY [resa]
Issue [fndg]
Identified [qlco]
Components [mnob]
Adverse event [fndg]
Profile [lbpr]
Observed [ftcn]
Fixed [fndg]
Dose Regimen [topp]
Combination [qlco]
Reported [inpr]
Adverse event [fndg]
Hypoglycaemia [dsyn]
confirmed [qlco]
Symptomatic [ftcn]
Hypoglycaemia [dsyn]
3 5 [qnco]
Subject [grup]
treated [topp]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
glimepiride [orch, phsu]
Conclusions [idcn]
Compared [acty]
rosiglitazone [orch, phsu]
glimepiride [orch, phsu]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
Improved [qlco]
glycemia [carb]
Increased [qnco]
Hypoglycaemia [dsyn]
Rosiglitazone + glimepiride [orch, phsu]
Fixed [fndg]
Dose [qnco]
Combination [qlco]
effective [qlco]
Well [qlco]
treatment option [topp]
Drug [phsu]
Diabetes Mellitus, Type 2 [dsyn]
